MAYAKU PHARMACEUTICAL DEVELOPMENT

Gent ·KBO/BCE: BE 0755.350.975

Loading dossier…

Year closed	Due by	Filed	Variance	Reference
31-12-2025	31-07-2026	nothing on record	not filed	-
31-12-2024	31-07-2025	27-06-2025	34 d early	2025-00208426
31-12-2023	31-07-2024	18-06-2024	43 d early	2024-00155221
31-12-2022	31-07-2023	29-06-2023	32 d early	2023-00200753
31-12-2021	31-07-2022	19-07-2022	12 d early	2022-20226534

Metric	This company	Sector median	Position in the sector
Solvency	-0.3%	46.9%	better than 25% of 46 sector peers
Net result	€5k	€-1k	better than 57% of 46 sector peers
Equity	€-262	€108k	better than 24% of 46 sector peers
Gross operating margin	€49k	€28k	better than 54% of 42 sector peers
Total assets	€99k	€284k	better than 26% of 46 sector peers

Line item	Code	2024
Balance sheet, Assets
TOTAL ASSETS	20/58	€99k
Fixed assets	21/28	€55k
Intangible fixed assets	21	€680
Tangible fixed assets	22/27	€54k
Financial fixed assets	28	€1k
Current assets	29/58	€44k
Stocks & contracts in progress	3	€4k
Amounts receivable within one year	40/41	€7k
Cash & bank	54/58	€23k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES	10/49	€99k
Equity	10/15	€-262
Contributions / capital	10/11	€2k
Accumulated profits (losses)	14	€-2k
Amounts payable	17/49	€99k
Amounts payable after one year	17	€68k
Amounts payable within one year	42/48	€32k
Trade debts payable within one year	44	€2k
Income statement
Gross operating margin	9900	€49k
Operating result	9901	€6k
Financial income	75	€74
Financial charges	65	€2k
Result before taxes	9903	€5k
Income taxes	67/77	€47
Net result for the period	9904	€5k
Result to be appropriated	9905	€5k

Summary

Legal nameNL	MAYAKU PHARMACEUTICAL DEVELOPMENT
AbbreviationNL	MAYAKU